N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis

Kidney International

Volumn 71, Issue 6, 2007, Pages 548-554

  Madsen, L H ^a   Ladefoged, S ^b   Corell, P ^a   Schou, M ^a   Hildebrandt, P R ^a   Atar, D ^c  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cardiac markers; End stage renal disease; Hemodialysis; NT proBNP; Volume status

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DIALYSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; URINALYSIS;

EID: 33947162081     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002087     Document Type: Article

References (38)

1. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4: 72-80.
2. Gustafsson F, Steensgaard-Hansen F, Badskjaer J et al. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail 2005; 11: S15-S20.
3. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-328.
4. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6: 257-260.
5. Wright SP, Doughty RN, Pearl A et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003; 42: 1793-1800.
6. Maisel A, Mehra MR. Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clin Cornerstone 2005; 7(Suppl 1): S7-S17.
7. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003; 8: 355-358.
8. Takahashi M, Nagake Y, Ichikawa H et al. Plasma concentrations of natriuretic peptides in patients on hemodialysis. Res Commun Mol Pathol Pharmacol 1996; 92: 19-30.
9. Ishibe S, Peixoto AJ. Methods of assessment of volume status and intercompartmental fluid shifts in hemodialysis patients: implications in clinical practice. Semin Dial 2004; 17: 37-43.
10. McDonagh TA, Holmer S, Raymond I et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004; 6: 269-273.
11. Clerico A, Caprioli R, Del RS, Giannessi D. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 2001; 24: 24-30.
12. Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 2004; 50: 1071-1074.
13. Zoccali C, Mallamaci F, Benedetto FA et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508-1515.
14. Cataliotti A, Malatino LS, Jougasaki M et al. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76: 1111-1119.
15. Osajima A, Okazaki M, Kato H et al. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol 2001; 21: 112-119.
16. Naganuma T, Sugimura K, Wada S et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol 2002; 22: 437-444.
17. Mallamaci F, Zoccali C, Tripepi G et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001; 59: 1559-1566.
18. Almeida SS, Azevedo A, Castro A et al. B-type natriuretic peptide is related to left ventricular mass in hypertensive patients but not in athletes. Cardiology 2002; 98: 113-115.
19. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004; 341: 41-48.
20. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction - comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med 2004; 42: 159-163.
21. Raymond I, Pedersen F, Steensgaard-Hansen F et al. Prevalence of impaired left ventricular systolic function and heart failure in a middle aged and elderly urban population segment of Copenhagen. Heart 2003; 89: 1422-1429.
22. Hildebrandt P, Boesen M, Olsen M et al. N-terminal pro brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004; 6: 313-317.
23. Raymond I, Groenning BA, Hildebrandt PR et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-751.
24. Maack T, Suzuki M, Almeida FA et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987; 238: 675-678.
25. Seymour AA, bboa-Offei BE, Smith PL et al. Potentiation of natriuretic peptides by neutral endopeptidase inhibitors. Clin Exp Pharmacol Physiol 1995; 22: 63-69.
26. Ng LL, Geeranavar S, Jennings SC et al. Diagnosis of heart failure using urinary natriuretic peptides. Clin Sci (London) 2004; 106: 129-133.
27. Ng LL, Loke IW, Davies JE et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 2005; 45: 1043-1050.
28. Maack T. Renal handling of low molecular weight proteins. Am J Med 1975; 58: 57-64.
29. Kistorp C, Raymond I, Pedersen F et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005; 293: 1609-1616.
30. Gardner RS, Ozalp F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24: 1735-1743.
31. Bettencourt P, Azevedo A, Pimenta J et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110: 2168-2174.
32. Kragelund CB, Gronning BA, Kober L et al. Prognostic value of N-terminal pro-BNP-type natriuretic peptide in patients with stable coronary heart disease - secondary publication. Ugeskr Laeger 2006; 168: 697-700.
33. Omland T, Persson A, Ng L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913-2918.
34. Olsen MH, Wachtell K, Tuxen C et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy. A LIFE study. J Hypertens 2004; 22: 1597-1604.
35. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004; 50: 2279-2285.
36. Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Rev Esp Cardiol 2005; 58: 1062-1092.
37. Kober L, Torp-Pedersen C, Carlsen J et al. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. Eur Heart J 1994; 15: 1616-1620.
38. O'Brien E, Asmar R, Beilin L et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23: 697-701.